Synergism between host anti-tumor immunity and combined modality therapy against murine breast cancer.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D000818:Animals; D000951:Antigens, Neoplasm; D003520:Cyclophosphamide / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D007111:Immunity, Cellular; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D008937:Mitomycins / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D009368:Neoplasm Transplantation; D013866:Thioguanine / Q000627:therapeutic use; D014184:Transplantation, Homologous
D000951:Antigens, Neoplasm; D008937:Mitomycins; D003609:Dactinomycin; D003520:Cyclophosphamide; D013866:Thioguanine